BCRX (BioCryst Pharmaceuticals) Growth Rank : 9 (As of Apr. 07, 2025)

View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Growth Rank?

BioCryst Pharmaceuticals has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of BioCryst Pharmaceuticals's Growth Rank

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCryst Pharmaceuticals's Growth Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Growth Rank distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Growth Rank falls into.

Save Embed

;

Save Embed

;

BioCryst Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

BO1:Germany BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Executives

Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Amy E Mckee	director	4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Theresa Heggie	director	4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703
Alan G Levin	director	ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Anthony Doyle	officer: Chief Financial Officer	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Steven K Galson	director	C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Charles K Gayer	officer: Vice President and CCO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes	officer: VP, General Counsel & Corp Sec	1929 BRASSFIELD ROAD, RALEIGH NC 27614
Jon P Stonehouse	director, officer: CEO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Michael L Jones	officer: Exec Director, Finance - PAO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu	officer: VP Drug Discovery	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244